Back to search

Article

Palbociclib and fulvestrant act in synergy to modulate central carbon metabolism in breast cancer cells

2018-06-16

Abstract excerpt

<h4>Summary</h4> Palbociclib, is a selective inhibitor of cyclin-dependent kinases 4 and 6 and used as a first-line treatment for patients with estrogen receptor positive breast cancer. It has been shown that patients have improved progression-free survival when treated in combination with fulvestrant, an estrogen receptor antagonist. However, the mechanisms for this survival advantage are not known. We sought to...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
7386e907-ff16-523c-a192-b7413f781e2a
DOI
10.1101/348722
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Palbociclib and fulvestrant act in synergy to modulate central carbon metabolism in breast cancer cellsDOI 10.1101/348722
Select a neighboring publication to make it the new centre.